PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide that acts as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Research investigations have focused on its unique mechanism of action, which operates through central neural pathways rather than peripheral vascular mechanisms, distinguishing it from other compounds studied in similar research contexts.
In clinical research settings, PT-141 has been studied for its effects on melanocortin receptor activation and downstream signaling cascades. Published investigations have examined its pharmacokinetic profile, with studies reporting peak plasma concentrations approximately one hour after subcutaneous administration and a half-life of approximately 2.7 hours. Research has explored its selectivity for central melanocortin receptors and its effects on neural arousal pathways.
Supplied as a lyophilized powder for reconstitution. Intended for research purposes only.
